Where available, however (currently only for “favorable risk” subtypes, e.g., APL, core binding factor leukemia, and NPM1-mutated AML), molecular methods are preferred because of their high reproducibility and inter-center standardization. The gene discussed is NPM1; the disease is acute myeloid leukemia.